EAM
NBIX icon

Eagle Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Eagle Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$78.1M Sell
621,363
-58,671
-9% -$8.04M 0.4% 90
2024
Q2 		$95.3M Sell
680,034
-33,491
-5% -$4.59M 0.51% 75
2024
Q1 		$101M Sell
713,525
-14,828
-2% -$2.03M 0.51% 71
2023
Q4 		$96M Buy
728,353
+1,074
+0.1% +$124K 0.51% 73
2023
Q3 		$81.8M Buy
727,279
+489
+0.1% +$51.5K 0.48% 82
2023
Q2 		$68.5M Buy
726,790
+448,619
+161% +$43.8M 0.38% 101
2023
Q1 		$28.2M Sell
278,171
-314
-0.1% -$32.7K 0.16% 146
2022
Q4 		$33.4M Buy
+278,485
New +$32.6M 0.21% 138
2016
Q4 		– Sell
-914,500
Closed -$46.3M – 654
2016
Q3 		$46.3M Sell
914,500
-27,153
-3% -$1.35M 0.31% 99
2016
Q2 		$42.8M Sell
941,653
-77,564
-8% -$3.57M 0.3% 109
2016
Q1 		$40.3M Sell
1,019,217
-83,863
-8% -$3.33M 0.28% 115
2015
Q4 		$62.4M Sell
1,103,080
-9,052
-0.8% -$460K 0.42% 77
2015
Q3 		$44.3M Sell
1,112,132
-213,937
-16% -$10.3M 0.3% 112
2015
Q2 		$63.3M Buy
1,326,069
+27,635
+2% +$1.17M 0.36% 101
2015
Q1 		$51.6M Buy
+1,298,434
New +$46.4M 0.3% 127

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eagle Asset Management's NBIX Position: Q3 2024 in Review

Eagle Asset Management reduced its Neurocrine Biosciences (NBIX) stake by 8.6% in Q3 2024, selling an estimated $8.04M and leaving 621,363 shares worth $78.1M. The position accounts for 0.4% of the portfolio, ranked #90.

Eagle Asset Management first reported a position in NBIX in Q1 2015 and has held it in 15 quarters since. The position peaked at $101M in Q1 2024. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Eagle Asset Management held 621,363 shares of Neurocrine Biosciences worth $78.1M as of Q3 2024.
  • Eagle Asset Management sold 58,671 Neurocrine Biosciences shares in Q3 2024, an estimated $8.04M.
  • Neurocrine Biosciences made up 0.4% of Eagle Asset Management's portfolio in Q3 2024, its #90 holding.
  • Eagle Asset Management first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 15 quarters since.
  • Eagle Asset Management's Neurocrine Biosciences position peaked at $101M in Q1 2024.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Eagle Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.